LPC20K modified from krill oil ameliorates the scopolamine-induced cognitive impairment
Behavioural Brain Research · 2024
DOI: 10.1016/j.bbr.2023.114836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Behavioural Brain Research, 2024. Verfasst von Keontae Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Pharmaceutical Science, Kyung Hee University, Seoul 02447, the Republic of Korea. Hauptthemen laut MEDLINE: Euphausiacea, Cognitive Dysfunction, Alzheimer Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Ministry of Education, Science and Technology, Ministry of Education Science and Technology, Korea Ministry of Science and ICT.
Abstract (Originalsprache)
Alzheimer's disease (AD) is characterized by cognitive impairment. It is common in the elderly. Etiologically, dysfunction of cholinergic neurotransmitter system is prominent in AD. However, disease modifying drug for AD is still unavailable. We hypothesized that krill oil and modified krill oil containing 20 % lysophosphatidylcholine-docosahexaenoic acid (LPC-DHA, LPC20K) could play a crucial role in AD by improving cognitive functions measured by several behavioral tests. We found that LPC20K could ameliorate short-term, long-term, spatial, and object recognition memory under cholinergic hypofunction states. To find the underlying mechanism involved in the effect of LPC20K on cognitive function, we investigated changes of signaling molecules using Western blotting. Expression levels of protein kinase C zeta (PKCζ) and postsynaptic density protein 95 (PSD-95), and phosphorylation levels of extracellular signal-regulated kinase (ERK), Ca2+/calmodulin-dependent protein kinase Ⅱ (CaMKⅡ), and cAMP response element-binding protein (CREB) were significantly increased in LPC20K-administered group compared to those in the memory impairment group. Moreover, the expression levels of BDNF were temporally increased especially 6 or 9 h after administration of LPC20K compared with the control group. These results suggest that LPC20K could ameliorate memory impairment caused by hypocholinergic state by enhancing the expression levels of PKCζ and PSD-95, and phosphorylation levels of ERK, CaMKⅡ and CREB and increasing BDNF expression levels. Therefore, LPC20K could be used as a dietary supplement against cognitive impairment observed in diseases such as AD with a hypocholinergic state.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Pharmaceutical Science, Kyung Hee University, Seoul 02447, the Republic of Korea.
- Croda Korea Ltd., Seongnam-si, Gyeonggi-do 13636, the Republic of Korea.
- Department of Biomedical and Pharmaceutical Science, Kyung Hee University, Seoul 02447, the Republic of Korea; Department of Oriental Pharmaceutical Science, Kyung Hee University, Seoul 02447, the Republic of Korea. Ele…
Förderung
- Ministry of Education, Science and Technology
- Ministry of Education Science and Technology
- Korea Ministry of Science and ICT
- Ministry of Science, ICT and Future Planning
- National Research Foundation of Korea
Zitieren
APA
Park, K., Kong, C. H., Kang, W. C., Jeon, M., Lee, W. H., Lee, J., Kim, S. C., Jung, S. Y., & Ryu, J. H. (2024). LPC20K modified from krill oil ameliorates the scopolamine-induced cognitive impairment. Behavioural Brain Research. https://doi.org/10.1016/j.bbr.2023.114836
Vancouver
Park K, Kong CH, Kang WC, Jeon M, Lee WH, Lee J, et al. LPC20K modified from krill oil ameliorates the scopolamine-induced cognitive impairment. Behavioural Brain Research. 2024. doi:10.1016/j.bbr.2023.114836
BibTeX
@article{Park2024,
author = {Park, Keontae and Kong, Chang Hyeon and Kang, Woo Chang and Jeon, Mijin and Lee, Won Hyung and Lee, Juyeon and Kim, Sang Chul and Jung, Seo Yun and Ryu, Jong Hoon},
title = {LPC20K modified from krill oil ameliorates the scopolamine-induced cognitive impairment},
journal = {Behavioural Brain Research},
year = {2024},
doi = {10.1016/j.bbr.2023.114836}
}
EUVIMED